41 |
Diferenciace totipotentních zárodečných buněk u larev ptačích schistosom / Differentiation of totipotent germinal cells in larvae of bird schistosomesPeštová, Jitka January 2015 (has links)
This thesis aims to explore the larval development of a bird fluke Trichobilharzia regenti in its intermediate hosts, as well as the processes of differentiation of its embryonal cells and the differentiation between sporocystogenesis and cercariogenesis in sporocysts, with the ultimate goal to find out whether it is possible to find multiple generations of daughter sporocysts throughout the development of avian schistosomes in the intermediate hosts, just like in the case of human schistosomes of genus Schistosoma. Five developmental stages of daughter sporocysts, and ten developmental stages of cercariae have been defined. The first developmental stage in both larvae is the germinal cell. It divides and gives rise to a cell agregate. Afterwards an envelope (primitive epithelium) is formed around the embryo and subsequently, the embryo elongates. At this stage, the development of the two larvae undergoes different pathways. We can distinguish daughter sporocyst from cercaria in the phase, when the tegument is completed. The daughter sporocyst acquires characteristic vermiform appearance, and its body cavity contains plenty of germinal cells. For cercariae with an developed tegument, presence of the penetration glands is characteristic. Key words: Trichobilharzia regenti, germinal cells, mother...
|
42 |
Ovarian Morphology, Oogenesis, and Changes through the Annual Reproductive Cycle of the Female Blue Crab, <em>Callinectes sapidus</em> Rathbun, in Tampa BayBrown, Catalina E 10 April 2009 (has links)
The blue crab, Callinectes sapidus Rathbun, 1896, was studied because of its high dollar value to Florida's commercial and recreational fisheries. The purpose of this study was to describe the structure of the ovary and oogenesis in the blue crab and the morphological changes in the female reproductive developmental stages over time. Histological techniques for high-resolution light microscopy were used to determine sexual maturity of female blue crabs. The ovarian morphology, oogenesis, and changes through the annual reproductive cycle of blue crabs in Tampa Bay were investigated for a period of two years, from January 2005 to January 2007. Ovarian structure was assessed by analyzing histological sections embedded in plastic epoxy resin, which provided a higher resolution than any other embedding material previously used in research on blue crab reproduction. Qualitative analyses of female gonads were made by describing the structure of the oocytes and determining the developmental stage of the oocytes from oogonia to full-grown oocytes. This study developed and introduced a new reproductive staging criteria for the species. Morphological characteristics of ovarian tissues and oocytes were determined to develop a classification for oocyte maturation stages. Morphological changes in the oocytes are well defined, and these were used to develop the staging schema.
In this study, it was found that carapace width is not a good indicator of maturity or developmental stage. Examination of the annual reproductive cycle indicates that late secondary growth occurs from July to March, and gravid crabs were found during November and December. Histological examination of ovarian tissue is essential for determining maturity in female blue crabs. By observing ovarian characteristics and by establishing the length of secondary growth during oogenesis in blue crabs of Tampa Bay, a more thorough understanding of the cyclic reproductive aspects of this species was obtained and specifically that animals at a carapace width between 100 mm and 125 mm may have mature oocytes, yet external features may not indicate that they are mature.
|
43 |
Prevalencia del Síndrome de Lynch en Pacientes con Cáncer de Endometrio no SeleccionadoEgoavil, Cecilia 26 September 2017 (has links)
El síndrome de Lynch (SL) es una condición hereditaria que aumenta el riesgo de cáncer endometrial y otros tipos de cáncer. La identificación de pacientes de cáncer de endometrio (CE) con SL tiene el potencial de influir en intervenciones que alteran el curso de la enfermedad e incrementan la expectativa de vida del sujeto afectado. Nuestro objetivo fue estudiar la prevalencia de SL entre los pacientes de CE en nuestra población. MÉTODOS: El cribado universal para SL se realizó en una serie de casos consecutivos de CE. Para seleccionar los casos sospechosos de SL se analizaron la inestabilidad de microsatélites (IMS), la inmunohistoquímica (IHC) por la expresión de las proteínas (MMR) y cuando fue necesario, el análisis de metilación de MLH1. Se realizó la secuenciación de los correspondientes genes MMR en los casos sospechosos de SL. RESULTADOS: 173 casos de CE (edad promedio, 63 años) fueron seleccionados. 61 pacientes (35%) tuvieron resultados de IHQ o IMS anormales. Después del análisis de metilación MLH1, 27 casos fueron considerados sospechosos de SL. De éstos, 22 pacientes fueron contactadas y remitidas para asesoramiento genético. 19 de ellas continuaron con pruebas genéticas y 8 fueron diagnosticadas de SL. Las mutaciones fueron más frecuentes en pacientes más jóvenes (<50 años). Tres casos tuvieron IHQ o MSS intacto, lo cual refuerza la necesidad de implementar el cribado de CE con ambas técnicas. Del estudio de familiares 68% (17/25) eran portadores de mutación (edad promedio, 39.6 años) 4 con neoplasia asociada al SL. CONCLUSIÓN: La prevalencia de SL en pacientes con CE fue de 4,6% (8/173); Con una frecuencia predictiva de 6,6% en la población española. Recomendamos el cribado universal de CE para SL.
|
44 |
Natural Killer Cell Regulation of Humoral ImmunityRydyznski, Carolyn E. 29 October 2018 (has links)
No description available.
|
45 |
Regulators of G-protein Signaling, RGS13 and RGS16, are Associated with CXCL12-mediated CD4+ T Cell MigrationXia, Lijin 06 August 2008 (has links) (PDF)
Chemokines are important chemical signals that guide lymphocyte movement within the immune system and promote the organization and functions of germinal centers (GCs) in the secondary lymphoid tissues. Previous studies have shown that GC T cells exhibit high expression of chemokine receptor 4, CXCR4, but that these cells are unable to migrate to the ligand for this receptor, the chemokine CXCL12. This “migratory paralysis” to CXCL12 was found to be correlated with the expression of two Regulators of G-protein Signaling, RGS13 and RGS16 in the GC T cells. The objective of my research was to determine whether RGS13 and RGS16 expression were associated with CXCL12-mediated CD4+ T cell migration. Because human GC T cells are rare and vary from one individual to another, I utilized two human neoplastic CD4+ T cell lines (i.e. Hut78 and SupT1) to facilitate and standardize my research. I also confirmed my observations using primary CD4+ T cells. Hut78 cells behaved similarly to GC T cells interms of CXCL12-mediated migration and RGS13 and RGS16 expression, while SupT1 cells appeared similar to CD4+ T cells that resided outside of GCs. The effect of RGS13 and RGS16 expression in the various CD4+ T cells was examined by altering the natural levels of these genes using RNA-mediated silencing and/or gene overexpression analysis after which, I examined the ability of the cells to migrate to CXCL12. RNA-mediated silencing of RGS16-, but not RGS13-, expression in Hut78 T cells resulted in a doubling of the migration rate in response to CXCL12. Over-expression of RGS13 or RGS16 in SupT1 and primary CD4+ T cells resulted in migration that was decreased by fifty percent. Because GC T cells demonstrated decreased migration to CXCL12 signals that may help them leave the GC, I reasoned that these cells may have an increased opportunity over other CD4+ T cells to become infected by the Human Immunodeficiency Virus (HIV) trapped on Follicular Dendritic Cells in the GCs of infected subjects. Examination of GC T cells obtained from HIV-infected subjects indicated that these cells were more frequently infected by HIV than other CD4+ T cells thereby confirming my postulate. My research indicated that RGS13 and RGS16 were associated with CXCL12-mediated CD4+ T cell migration and suggests that these molecules may play an important role in HIV pathogenesis within the GC.
|
46 |
THE CYTOLOGY OF SPERMATOGENESIS AND ULTRASTRUCTURE OF THE SEMINIFEROUS EPITHELIUM IN REPTILESGRIBBINS, KEVIN MICHAEL 30 June 2003 (has links)
No description available.
|
47 |
The Role of Histone Deacetylase 6 Inhibition on Systemic Lupus ErythematosusRen, Jingjing 13 September 2019 (has links)
Systemic lupus erythematosus (SLE) is a chronic multifactorial inflammatory autoimmune disease with heterogeneous clinical manifestations. Among different manifestations, lupus nephritis (LN) remains a major cause of morbidity and mortality. There are few FDA approved treatments for LN. In general, they are non-selective and lead to global immunosuppression with significant side effects including an increased risk of infection. In the past 60 years, only one new drug, belimumab was approved for lupus disease with modest efficacy in clinic and not approved for patients suffering for nephritis. Therefore, it is urgent to develop new treatments to replace or reduce the use of current ones.
Histone deacetylase 6 (HDAC6) plays a variety of biologic functions in a number of important molecular pathways in diverse immune cells. Both innate and adaptive immune cells contribute to pathogenesis of lupus. Among those cells, B cells play a central role in pathogenesis of lupus nephritis in an anti-body dependent manner through differentiation into plasma cells (PCs). As a result, HDAC6 inhibitors represent an entirely new class of agents that could have potent effects in SLE. Importantly, the available toxicity profile suggests that HDAC6 inhibitors could be advanced into SLE safely.
We have demonstrated previously that histone deacetylase (HDAC6) expression is increased in animal models of systemic lupus erythematosus (SLE) and that inhibition of HDAC6 decreased disease. ACY-738 is a hydroxamic acid HDAC6 inhibitor that is highly selective for HDAC6. In our current studies, we tested if an orally selective HDAC6 inhibitor, ACY-738, would decrease disease pathogenesis in a lupus mouse model with established early disease. Moreover, we sought to delineate the cellular and molecular mechanism(s) of action of a selective HDAC6 inhibitor in SLE. In order to define the mechanism by which HDAC6 inhibition decreases disease pathogenesis in NZB/W mice by using RNAseq to evaluate the transcriptomic signatures of splenocytes from treated and untreated mice coupled with applied computational cellular and pathway analysis. In addition, we sought to bridge between the transcriptomic data obtained from the HDAC6 treated mice and human gene expression information to determine the relevance to this target in possibly controlling human lupus.
We treated 20-week-old (early-disease) NZB/W F1 female mice with two different doses of the selective HDAC6 inhibitor (ACY-738) for 4~5 weeks. As the mice aged, we determined autoantibody production and cytokine levels by ELISA, and renal function by measuring proteinuria. At the termination of the study, we performed a comprehensive analysis on B cells, T cells, and innate immune cells using flow cytometry and examined renal tissue for immune-mediated pathogenesis using immunohistochemistry and immunofluorescence. We then used RNAseq to determine the genomic signatures of splenocytes from treated and untreated mice and applied computational cellular and pathway analysis to reveal multiple signaling events associated with B cell activation and differentiation in SLE that were modulated by HDAC6 inhibition.
Our results showed a reduced germinal center B cell response, decreased T follicular helper cells and diminished interferon (IFN)-γ production from T helper cells in splenic tissue. Additionally, we found the IFN-α-producing ability of plasmacytoid dendritic cells was decreased along with immunoglobulin isotype switching and the generation of pathogenic autoantibodies. Renal tissue showed decreased immunoglobulin deposition and reduced inflammation as judged by glomerular and interstitial inflammation.
The molecular pathways by which B cells become pathogenic PC secreting autoantibodies in SLE are incompletely characterized. RNA sequence data showed that PC development was abrogated and germinal center (GC) formation was greatly reduced. When the HDAC6 inhibitor-treated lupus mouse gene signatures were compared to human lupus patient gene signatures, the results showed numerous immune and inflammatory pathways increased in active human lupus were significantly decreased in the HDAC6 inhibitor treated animals. Pathway analysis suggested alterations in cellular metabolism might contribute to the normalization of lupus mouse spleen genomic signatures, and this was confirmed by direct measurement of the impact of the HDAC6 inhibitor on metabolic activities of murine spleen cells.
Taken together, these studies show selective HDAC6 inhibition decreased several parameters of disease pathogenesis in lupus-prone mice. The decrease was in part due to inhibition of B cell development and response. RNA sequence data analysis show HDAC6 inhibition decreases B cell activation signaling pathways and reduces PC differentiation in SLE and suggests that a critical event might be modulation of cellular metabolism. / Doctor of Philosophy / Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease by which immune cells mistakenly attacks healthy self-cells in different organs. Kidney inflammation occurs in nearly 50% of patients with lupus resulting in kidney damage leading to end stage renal disease. Lupus nephritis (LN) is major cause of morbidity and mortality associated with SLE. Current treatments for LN consist primarily of immunosuppressants that block the immune response and leave the patients with unwanted side effects including an increased risk of infection. To circumvent the unwanted side effects, we explored a novel mechanism to target the immune response. My project was to determine whether histone deacetylase 6 (HDAC6) inhibition would suppress the autoimmune inflammatory response in lupus. We found that inhibition of HDAC6 was effective at attenuating early LN, probably by down-regulating innate immune response, which suppressed subsequent adaptive immune responses downstream. HDAC6 inhibition affected the innate immune response by inhibiting type I interferon production by plasmacytoid dendritic cells. HDAC6 inhibition affected the cell mediated immune response by decreasing T helper cell and B cell activation. To determine the mechanism by which HDAC6 inhibits immune cells activation, we used RNAseq to reveal HDAC6 inhibition on multiple signaling events associated with the induction of lupus disease. These results suggest that HDAC6 could be a potential therapeutic target in the early stage of LN.
|
48 |
Associations Between Rheumatoid Arthritis and Malignant LymphomasBaecklund, Eva January 2005 (has links)
<p>Patients with rheumatoid arthritis (RA) are at increased risk of developing malignant lymphoma, although details about this association remain unclear. The aims of this thesis were to investigate risk factors for lymphoma in patients with RA and to characterize these lymphomas regarding subtype, presence of Epstein-Barr virus (EBV), clinical manifestations and prognosis. </p><p>The Swedish hospital discharge register and the cancer register were used to identify RA patients with lymphoma. Two case-control studies were performed, one smaller including RA patients with lymphoma hospitalised in Uppsala health care region 1964-1983 (n=41) and one larger study of hospitalised RA patients with lymphoma in Sweden 1964-1995 (n=378). RA patients from the same cohorts, but without lymphoma, were matched as controls. Medical records for cases and controls were scrutinized for exposure information. The lymphoma tissues were reclassified according to the WHO classification, and presence of EBV was analysed by EBER in situ hybridisation.</p><p>The most important risk factor for lymphoma development was high RA disease activity. No association was determined between treatment with traditional disease modifying drugs, non-steroidal anti-inflammatory drugs, aspirin, peroral and intra-articular corticosteroids and lymphoma risk. Diffuse large B-cell lymphoma (DLBCL) was more frequent in RA patients than in lymphoma patients in the general population and displayed stronger association with RA disease activity than other lymphoma subtypes. RA patients with DLBCL had increased extranodal involvement and more advanced lymphoma stage at presentation than DLBCL patients in general, and the prognosis was poor. </p><p>A further subdivision of DLBCL into germinal centre (GC) and non-GC subtypes by the expression patterns of CD10, bcl-6 and IRF-4 showed a predominance of the non-GC subtype. This suggested peripheral activated B-cells as the cells of origin in these lymphomas. </p><p>The presence of EBV was low in lymphomas in RA patients (12%). </p>
|
49 |
Associations Between Rheumatoid Arthritis and Malignant LymphomasBaecklund, Eva January 2005 (has links)
Patients with rheumatoid arthritis (RA) are at increased risk of developing malignant lymphoma, although details about this association remain unclear. The aims of this thesis were to investigate risk factors for lymphoma in patients with RA and to characterize these lymphomas regarding subtype, presence of Epstein-Barr virus (EBV), clinical manifestations and prognosis. The Swedish hospital discharge register and the cancer register were used to identify RA patients with lymphoma. Two case-control studies were performed, one smaller including RA patients with lymphoma hospitalised in Uppsala health care region 1964-1983 (n=41) and one larger study of hospitalised RA patients with lymphoma in Sweden 1964-1995 (n=378). RA patients from the same cohorts, but without lymphoma, were matched as controls. Medical records for cases and controls were scrutinized for exposure information. The lymphoma tissues were reclassified according to the WHO classification, and presence of EBV was analysed by EBER in situ hybridisation. The most important risk factor for lymphoma development was high RA disease activity. No association was determined between treatment with traditional disease modifying drugs, non-steroidal anti-inflammatory drugs, aspirin, peroral and intra-articular corticosteroids and lymphoma risk. Diffuse large B-cell lymphoma (DLBCL) was more frequent in RA patients than in lymphoma patients in the general population and displayed stronger association with RA disease activity than other lymphoma subtypes. RA patients with DLBCL had increased extranodal involvement and more advanced lymphoma stage at presentation than DLBCL patients in general, and the prognosis was poor. A further subdivision of DLBCL into germinal centre (GC) and non-GC subtypes by the expression patterns of CD10, bcl-6 and IRF-4 showed a predominance of the non-GC subtype. This suggested peripheral activated B-cells as the cells of origin in these lymphomas. The presence of EBV was low in lymphomas in RA patients (12%).
|
50 |
Regulation of the germinal center reaction by T helper cells and T regulatory cellsWu, Hao 11 April 2016 (has links)
Indiana University-Purdue University Indianapolis (IUPUI) / Germinal Centers (GCs) are transient lymphoid structures that arise in lymphoid organs in response to T cell-dependent antigen. Within the GC, follicular T helper (TFH) cells promote GC B cell differentiation and in turn the proper antibody production to protect us from invading pathogens. We wished to study the regulation of this process by transcription factors STAT3 and Bcl6. STAT3 is important for both TFH cell differentiation and IL-4 production by Th2 cells. IL-4 is a major functional cytokine produced by TFH cells. To dissect the role of STAT3 in IL-4 production by TFH cells, we generated T cell-specific conditional STAT3 knockout mice (STAT3KO). Compared to WT mice, TFH cell differentiation in STAT3KO mice was partially impaired, both in spleen following sheep red blood cells (SRBC) immunization and in Peyer's patches (PPs). In STAT3KO mice, the numbers of splenic GC B cells were markedly decreased, whereas PP GC B cells developed at normal numbers and IgG1 class switching was greatly increased. Unexpectedly, we found that STAT3 intrinsically suppressed the expression of IL-4 and Bcl6 in TFH cells. Mechanistically, in vitro repression of IL-4 expression in CD4 T cells by Bcl6 required STAT3 function. Apart from TFH cells, the GC reaction is also controlled by regulatory follicular T helper (TFR) cells, a subset of Treg cells. To study the mechanism of how TFR cells regulate the GC reaction, we generated mice specifically lacking TFR cells by specifically deleting Bcl6 in Treg cells. Following immunization, these "Bcl6FC" mice developed normal TFH and GC B cell populations. However, Bcl6FC mice produced altered antigen-specific antibody responses, with reduced titers of IgG and increased IgA. Bcl6FC mice also developed IgG antibodies with significantly decreased avidity to antigen in an HIV-1 gp120 "prime-boost" vaccine model. Additionally, TFH cells from Bcl6FC mice produced higher levels of Interferon-γ, IL-10 and IL-21. Loss of TFR cells therefore leads to highly abnormal TFH and GC B cell responses. Overall, our studies have uncovered unexpected regulatory roles of STAT3 in TFH cell function as well as the novel regulatory roles of TFR cells on cytokine production by TFH cells and on antibody production.
|
Page generated in 0.0674 seconds